Breast oncology precision medicine: Genomic testing and treatment at the population level.

Authors

Christopher Friese

Christopher Ryan Friese

University of Michigan, Ann Arbor, MI

Christopher Ryan Friese, Yun Li, Allison W. Kurian, Steven J. Katz

Organizations

University of Michigan, Ann Arbor, MI, Stanford University Medical Center, Stanford, CA

Research Funding

No funding sources reported

Background: The 21-gene assay used to estimate breast cancer recurrence and tailor chemotherapy (chemo) receipt has demonstrated predictive validity and clinical utility. Yet it is unclear how involved patients are in the decision to perform the test, or how oncologists use results to recommend systemic chemo. We examined the patient experience with assay testing, physician recommendations, and chemo receipt based on test results. Methods: The iCanCare study surveyed a weighted random sample of newly diagnosed patients with early-stage breast cancer who were treated in 2013-14, identified through the population-based SEER registries of Los Angeles and Georgia about 3 months after surgical treatment, and merged with SEER data (N=2632, RR=70%). Registries partnered with Genomic Health, Inc. to link assay results to patients. We examined validated results against patient self report; patient satisfaction with testing and chemo decisions (1= not at all satisfied; 5= very satisfied); physician chemo recommendations, and; chemo receipt based on test scores (0-10= low risk; 30-100= high risk for recurrence). Results: Of the 1,908 women with invasive disease, 1,307 (68.5%) women had lower-risk features (Stage 1a/b, 2a, ER-positive, HER-2 negative) and 695 (53.2%) of them had tests performed. Of those tested, 60% recalled scores accurately. Most women were satisfied with their communication with doctors about testing (93%) and the chemo decision (90%). Testing varied slightly across risk groups: Grade 1 or 2 disease (54%), Grade 3 disease (61%), and any node-positive disease (62%). Most (91%) women with high-risk scores (>30) reported their oncologist recommended chemo. Fewer (65%) women with low-risk scores (<10) reported recommendations against chemo. Chemo receipt rates varied by risk scores: 2% for low-risk scores and 66% for high-risk scores. Conclusions: Most women were satisfied with testing and chemo decisions, yet many patients do not accurately recall test scores. Testing is higher in uncertain clinical groups. Physician recommendations and chemo receipt are tightly linked to test scores, suggesting that precision medicine has tailored treatment effectively to women with breast cancer. Funding: P01CA163233

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2016 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B: Science of Quality

Track

Cost, Value, and Policy in Quality,Practice of Quality,Science of Quality

Sub Track

Studies Using Registries or Combining Large Databases

Citation

J Clin Oncol 34, 2016 (suppl 7S; abstr 288)

DOI

10.1200/jco.2016.34.7_suppl.288

Abstract #

288

Poster Bd #

M4

Abstract Disclosures

Similar Abstracts